Communiqués Summit Therapeutics Inc.

Actions

SMMT

US86627T1088

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 02/07/2026			Varia. 5j.	Varia. 1 janv.
15,42 ^USD	+7,23%		+10,06%	-11,84%

12/06	Summit Therapeutics : un initié acquiert pour près de 50 millions de dollars d'actions, selon un document de la SEC	MT
11/06	Summit Therapeutics renonce à son augmentation de capital en raison des conditions de marché	MT

Communiqués

09/06	Summit Therapeutics Announces Proposed Public Offering of Common Stock	BU
04/06	Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference	BU
31/05	Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non-small cell lung cancer: Overall survival results of the Phase 3 HARMONi-6 Slides	PU
31/05	Summit Therapeutics : Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China	PU
31/05	Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China	BU
30/05	A randomized, active-controlled phase 3 study of ivonescimab FOLFOX versus bevacizumab FOLFOX as first-line treatment of metastatic colorectal cancer: HARMONi-GI3	PU
30/05	Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026	BU
30/04	Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026	BU
27/03	Health-Related Quality of Life in Patients Previously Treated With an EGFR-TKI From HARMONi: A Phase 3 Trial of Ivonescimab vs Placebo Plus Chemotherapy	PU
27/03	Health-Related Quality of Life With Ivonescimab Versus Pembrolizumab for PD-L1 Positive, Non–Small Cell Lung Cancer (HARMONi-2): A Randomised, Double-Blind, Phase 3 Study in China	PU
27/03	Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026	BU
27/02	Summit Therapeutics to Present at Upcoming Investor Conferences	BU
23/02	Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025	BU
17/02	Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026	BU
30/01	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
30/01	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy	AQ
29/01	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy	BU
12/01	Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)	BU
12/01	Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC	BU
10/01	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
06/01	Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference	BU
05/12	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
07/11	Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China	BU
04/11	Summit Therapeutics to Present at Upcoming Investor Conferences	BU
03/11	Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025	AQ